Australia’s leading contract research organization focused exclusively on
medicinal cannabis treatments

About us

Accelerate your medicinal cannabis clinical development program. From project management through to clinical trial monitoring, management and patient recruitment, we’re Australia’s leading contract research organization in the medicinal cannabis sector.

Medicinal Cannabis Research needs a different approach. Intellectual property positions are different. Budgets are smaller. Timescales are shorter. Regulatory pathways are newly established and more complex. Product companies undertaking research in the Medicinal Cannabis sector need a different research partner. A partner with hands-on experience in the sector; direct access to the largest patient pool in the country; multiple treatment sites in every state; data collection platforms that are compliant, and tailored to the medicinal cannabis sector.

Applied Cannabis Research is dedicated to assisting medicinal cannabis companies with the development of their products with a single, unified vision: the faster the clinical development stage is accomplished the quicker medicinal cannabis treatments reach those who need them – the patients.

Why Australia for Cannabis Research?

Federally Legal Medicinal Cannabis Framework.

Australia legalized medicinal cannabis in 2016. Although patient update was slow at first, doctor and patient numbers are now increasing rapidly. Applied Cannabis Research has direct access to the largest patient pool in the country with recruitment sites in every state.

A distinct advantage to conducting clinical research

Australia and New Zealand has the expeditious CTN (clinical trial notification) scheme. Australia’s regulator, the TGA requires only a notification of a clinical trial, deferring responsibility to the HREC (Human Research Ethics Committee – equivalent of an IRB) resulting in faster study start-up. Applied Cannabis Clinics HREC’s meet weekly and can approve trials on the same day.

Pharmaceutical Approach

Products legally prescribed in Australia must be pharmaceuticals with known and tightly specified amounts of cannabinoids. They are manufactured in regulator-approved GMP facilities and must meet Australian medicinal cannabis quality standard TGO93. Products are prescribed in exact dosages and patients are monitored on a regular basis. All of these aspects of our medicinal cannabis framework make Australia a perfect location to carry out research that requires precision, control and reporting.

R&D Tax benefits

Australia has a strongly advantageous R&D tax scheme that for smaller companies will pay 45% of your investment as a cash-rebate, with an equivalent amount payable on overseas spend. Larger companies receive a tax rebate rather than a cash payment. This means that for most companies up to 90% of the money spend in Australia on R&D can be returned in some form.

Who we work with

Our team

Dr Natalie Beveridge

Natalie leads the CACOS Study, Australia’s largest medicinal cannabis observational study. She is also a principal investigator on other studies run by Applied Cannabis Research. Natalie has lectured at the School of Biomedical Sciences and Pharmacy at the University of Newcastle and was visiting scientist at the Clinical Brain Disorders Branch of the National Institutes of Health, USA.

Natalie completed her PhD Studies at the University of Newcastle in Microbiology and Immunology and received the Beryl Nashar young researcher award and Schizophrenia Research Institute scholarship.

Dr Abdolvahab (Vahab) Baghbanian

Dr Abdolvahab (Vahab) Baghbanian – Vahab has academic qualifications at Doctoral (PhD), Master, Bachelor and Graduate Levels with a focus on public health policy, social science, economics and mental related issues in health. He has previously served as an academic, data analyst, advisor and consultant to several regional, national and international governmental institutions.

Vahab has been commissioned to conduct several national and international training courses, research projects and workshops on the administrative, economic and policy aspects of health care, mental health and social sciences, including behavioural community health, mental disorders, drug abuse, rehabilitation counselling, ageing, disability, equity of access to health care, social media, social determinants of health, economic evaluation of health interventions, and immigration and emigration.